– ISRAEL, Nes Ziona – Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the appointment of Dr. Brian Schwartz, MD to its Board of Directors, effective on November 15, 2020.
“We are excited to have Dr. Schwartz on our Board. He has significant relevant experience in all aspects of the product development lifecycle and shareholder value creation. We look forward to working together.” said Executive Chairman, Shai Novik.
Dr. Schwartz served for twelve years as Chief Medical Officer of ArQule, Inc. and led ArQule’s research and development programs through its $2.7 billion acquisition by Merck earlier this year,.
Dr. Schwartz commented, “I am excited to be joining the Board of Directors of Enlivex. After carefully reviewing the scientific basis and data for Allocetra, which is currently in clinical development for sepsis and COVID-19, and in preclinical development for solid cancers, I believe that this innovative immunotherapy approach has the potential to significantly impact life-threatening, high-mortality diseases. Additionally, I believe that the planned and ongoing clinical program, coupled with a management team that has a track record of creating shareholder value, leaves the Company well-positioned for sustained near- and long-term growth.”
About Dr. Brian Schwartz
Dr. Schwartz brings significant experience in drug development in both the biotechnology and pharmaceutical industries. Dr. Schwartz most recently served as Chief Medical Officer and Head of Research and Development of ArQule, Inc. where he served as a key member of the management team and spearheaded several preclinical and clinical drug development programs in oncology and rare diseases. Before joining ArQule in 2008, Dr. Schwartz served as Chief Medical Officer and Senior Vice President, Clinical and Regulatory Affairs, at Ziopharm Oncology, Inc., where he built and led clinical, regulatory, and quality assurance departments responsible for the development of new cancer drugs. Earlier in his career, Dr. Schwartz held several positions at Bayer Healthcare and Leo Laboratories. At Bayer, Dr. Schwartz was a key physician responsible for the global clinical development of sorafenib and has extensive regulatory experience working with the FDA’s Oncology Division, the European Medicines Evaluation Agency, and numerous other health authorities.
Dr. Schwartz received his medical degree from the University of Pretoria, South Africa, practiced medicine, and worked at the University of Toronto before his career in the biopharmaceutical industry.
Dr. Schwartz currently serves as a board member of Mereo Biopharma and LifeSci Acquisition Corp.
About Enlivex
Enlivex is a clinical-stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines and for which there are no approved treatments such as sepsis and COVID-19, as well as enhancement of immune activity against solid tumors in combination with CAR-T or immune checkpoint therapies.
For more information: https://www.enlivex.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.